Celon Pharma S.A. Stock price

Equities

CLN

PLCLNPH00015

Pharmaceuticals

Market Closed - Warsaw S.E. 12:55:43 2024-03-28 pm EDT 5-day change 1st Jan Change
15.12 PLN -0.40% Intraday chart for Celon Pharma S.A. +0.67% -2.20%
Sales 2023 * 216M 54.1M Sales 2024 * 249M 62.34M Capitalization 772M 193M
Net income 2023 * -16M -4.01M Net income 2024 * -20M -5.01M EV / Sales 2023 * 3.21 x
Net cash position 2023 * 79M 19.8M Net cash position 2024 * 46.55M 11.67M EV / Sales 2024 * 2.92 x
P/E ratio 2023 *
-116 x
P/E ratio 2024 *
-37.5 x
Employees 513
Yield 2023 *
0.6%
Yield 2024 *
0.62%
Free-Float 41.19%
More Fundamentals * Assessed data
Dynamic Chart
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases CI
Celon Pharma to Raise PLN 216mn in Public Offering CI
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes CI
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial CI
Celon Pharma Seeks Partner for Salmex CI
More news
1 day-0.40%
1 week+0.67%
Current month+0.80%
1 month-0.53%
3 months-2.20%
6 months-0.92%
Current year-2.20%
More quotes
1 week
14.64
Extreme 14.64
15.22
1 month
14.62
Extreme 14.62
15.82
Current year
14.62
Extreme 14.62
16.10
1 year
13.10
Extreme 13.1
17.94
3 years
12.00
Extreme 12
52.80
5 years
12.00
Extreme 12
57.00
10 years
12.00
Extreme 12
57.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-06-19
Director of Finance/CFO - 21-12-14
Investor Relations Contact - 17-07-31
Members of the board TitleAgeSince
Chairman - -
Director/Board Member - -
Director/Board Member 62 21-02-15
More insiders
Date Price Change Volume
24-03-28 15.12 -0.40% 8,455
24-03-27 15.18 +2.71% 13,780
24-03-26 14.78 -1.20% 10,309
24-03-25 14.96 -0.40% 13,062
24-03-22 15.02 0.00% 4,505

Delayed Quote Warsaw S.E., March 28, 2024 at 12:55 pm EDT

More quotes
Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
15.12 PLN
Average target price
16.5 PLN
Spread / Average Target
+9.13%
Consensus
  1. Stock
  2. Equities
  3. Stock Celon Pharma S.A. - Warsaw S.E.